Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
There is an urgent need for new genetic biomarkers which enable the selection of optimal drugs. Single nucleotide polymorphisms (SNP) are known to affect the outcome of anticancer drugs used in the management of cancers. They may be used as noninvasive prognostic and predictive biomarkers to guide personalized treatment decisions. Creative Biolabs is well equipped and versed in high-throughput SNP genotyping for Biomarker Discovery. We are glad to serve our global clients with professionalism and expertise in SNP genotyping.
SNPs are the most frequently occurring genetic variation in the DNA sequence. They involve a single base and have a frequency of greater than 1% in at least one minor allele population. The total number of SNPs in the human genome exceeding 9 million. They are important biomarkers in many studies that link sequence variations to phenotypic changes, elucidating the molecular bases of diseases. Certain SNPs have already been identified as potential predictors of efficacy and/or toxicity in renal cell carcinoma (RCC) patients treated with tyrosine kinase inhibitors. Moreover, SNPs prove to be important determinants in evaluating and predicting a patient's response and to treatment and risk of adverse events.
Over the past few years, Creative Biolabs has devoted a great deal of effort to developing accurate, rapid, and cost-effective technologies for SNP analysis. Our scientists have developed several SNP genotyping technologies, depending on the species, the number of SNPs per sample, applications, and purpose, as follows.
For SNP genotyping by NGS, scientists at Creative Biolabs are proficient at retrieving information related to the genes identified in the common and rare variant analysis for biomarker discovery. Common SNP association analysis is performed using univariable and multivariable logistic regression while rare-variant association analysis is performed using a multi-marker test.
With proven experience in SNP genotyping for biomarker discovery, Creative Biolabs is an ideal company to entrust with your business. Our comprehensive portfolio provides reliable and accurate SNP analysis to help our clients' genetic biomarker development project. For more information, please feel free to contact us and further discuss with our scientists.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
